Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Príomhchruthaitheoir: | Paul, Pulock |
---|---|
Rannpháirtithe: | Azam,Faruque |
Formáid: | Tráchtas |
Teanga: | English |
Foilsithe / Cruthaithe: |
Brac University
2024
|
Ábhair: | |
Rochtain ar líne: | http://hdl.handle.net/10361/23954 |
Míreanna comhchosúla
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
de réir: Rahman, Tasnim
Foilsithe / Cruthaithe: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
de réir: Hoque, Ismoth Ara
Foilsithe / Cruthaithe: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
de réir: Karim, Samia Binte
Foilsithe / Cruthaithe: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
de réir: Flora, Sanzida Alam
Foilsithe / Cruthaithe: (2024) -
A review on targeted therapies for lung cancer
de réir: Ashraf, Anushey
Foilsithe / Cruthaithe: (2023)